Skip to content
Screener

Arbutus Biopharma Corporation ABUS Cash & Equivalents

Cash & Equivalents at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
Gilead Sciences logo
Gilead SciencesGILD
$3.18B-38.2%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+53.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$85.61M+101%
Assembly Biosciences logo
Assembly BiosciencesASMB
$31.12M+32.9%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$896.82M+42.4%
Enterprise value$873.75M+47.1%
P/E5.6×—
P/S4.7×-36.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
FINANCING ACTIVITIES
Issuance of common shares pursuant to exercise of stock options11,5312,653
Issuance of common shares pursuant to ESPP88131
Net cash provided by financing activities11,6192,784
Effect of foreign exchange rate changes on cash and cash equivalents(10)4
Increase in cash and cash equivalents5,698746
Cash and cash equivalents, beginning of period18,00836,330
Cash and cash equivalents, end of period$23,706$37,076

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's cash & equivalents?
Arbutus Biopharma Corporation (ABUS) reported cash & equivalents of $23.71M in Q1 2026.
How has Arbutus Biopharma Corporation's cash & equivalents changed year-over-year?
Arbutus Biopharma Corporation's cash & equivalents decreased by 36.1% year-over-year, from $37.08M to $23.71M.
What is the long-term trend for Arbutus Biopharma Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's cash & equivalents has grown at a -19.2% compound annual growth rate (CAGR), from $52.25M to $18.01M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Arbutus Biopharma Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude